IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with IDE161, a PARG inhibitor, in DLL3-upregulated solid tumors such as ...
The FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for ...
From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.
Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.
Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA will progress its ADC Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has shown ...
The "ADC Contract Manufacturing Market (7th Edition): Distribution by Stage of Development, Process Component, Type of Payload, Antibody Isotype, Target Indication, Antibody Origin, Type of Linker, ...
A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer. Age and insurance status were ...
Ovarian cancer is hard to diagnose early. Its symptoms, like bloating and abdominal pain, are vague and similar to other more common conditions. Early diagnosis improves outcomes for many cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results